UY25436A1 - Combinaciones de estatina-inhibidor de mmp - Google Patents
Combinaciones de estatina-inhibidor de mmpInfo
- Publication number
- UY25436A1 UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
- Authority
- UY
- Uruguay
- Prior art keywords
- mmp inhibitor
- statin
- inhibitor combinations
- combination
- ldl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una combinación de un compuesto de estatina,que se sabe que causa una reducción en los niveles plasmáticos de colesterol lipoproteínas de baja densidad (ldl),y un inhibidor de mmp,que reduce la ruptura de tejidos conectivos. La combinación es útil para tratar trastornos vasculares y prevenir la insuficiencia cardiaca.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25436A1 true UY25436A1 (es) | 2001-10-25 |
Family
ID=22142950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25436A UY25436A1 (es) | 1998-03-17 | 1999-03-16 | Combinaciones de estatina-inhibidor de mmp |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1063991A1 (es) |
JP (1) | JP2002506818A (es) |
KR (1) | KR20010041916A (es) |
AR (1) | AR018113A1 (es) |
AU (1) | AU1591699A (es) |
BR (1) | BR9815745A (es) |
CA (1) | CA2309588A1 (es) |
CO (1) | CO5070670A1 (es) |
GT (1) | GT199900039A (es) |
HN (1) | HN1999000029A (es) |
MY (1) | MY140504A (es) |
NZ (1) | NZ505994A (es) |
PA (1) | PA8469001A1 (es) |
PE (1) | PE20000348A1 (es) |
SV (1) | SV1999000026A (es) |
UY (1) | UY25436A1 (es) |
WO (1) | WO1999047138A1 (es) |
ZA (1) | ZA992106B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
RU2410118C2 (ru) | 2004-12-15 | 2011-01-27 | Зольвай Фармасьютиклз Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ |
SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9611410A (pt) * | 1995-11-02 | 1999-01-05 | Warner Lambert Co | Método e composição farmacêutica para regular a concentração de lipídios |
PL186416B1 (pl) * | 1996-05-17 | 2004-01-30 | Warner Lambert Co | Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. |
-
1998
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/ja active Pending
- 1998-11-20 NZ NZ505994A patent/NZ505994A/xx unknown
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/ko not_active Application Discontinuation
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Application Discontinuation
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/pt not_active Application Discontinuation
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/es unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/es unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/es not_active Application Discontinuation
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/es unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/es not_active Application Discontinuation
- 1999-03-16 CO CO99016109A patent/CO5070670A1/es unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/xx unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/es not_active Application Discontinuation
- 1999-03-16 GT GT199900039A patent/GT199900039A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PA8469001A1 (es) | 2002-09-17 |
AU1591699A (en) | 1999-10-11 |
CA2309588A1 (en) | 1999-09-23 |
BR9815745A (pt) | 2000-11-14 |
NZ505994A (en) | 2003-10-31 |
JP2002506818A (ja) | 2002-03-05 |
SV1999000026A (es) | 2000-01-18 |
CO5070670A1 (es) | 2001-08-28 |
GT199900039A (es) | 2000-09-06 |
HN1999000029A (es) | 1999-09-29 |
KR20010041916A (ko) | 2001-05-25 |
ZA992106B (en) | 1999-09-30 |
MY140504A (en) | 2009-12-31 |
AR018113A1 (es) | 2001-10-31 |
WO1999047138A1 (en) | 1999-09-23 |
EP1063991A1 (en) | 2001-01-03 |
PE20000348A1 (es) | 2000-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP074704A (es) | Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares | |
AR032403A1 (es) | Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares | |
UY25268A1 (es) | Inhibicion de la oxidacion de lipoproteinas | |
DK0840732T3 (da) | Substituerede benzolactamforbindelser som substans P-antagonister | |
EA200100707A1 (ru) | Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний | |
PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
EA199800667A1 (ru) | Новые фенантридины | |
UY25322A1 (es) | Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis | |
UY25299A1 (es) | Combinaciones de estatina-eter carboxialquílico | |
BR9911440A (pt) | Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa | |
BR0212252A (pt) | Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero | |
ECSP034782A (es) | Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso | |
HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
EP0793489A4 (en) | AGENTS FOR TREATING SKIN DISEASES | |
EE200100155A (et) | Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
NZ503962A (en) | ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis | |
PT1032414E (pt) | Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias | |
PT1109571E (pt) | Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos | |
UY25436A1 (es) | Combinaciones de estatina-inhibidor de mmp | |
BR9713522A (pt) | Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos. | |
DK0885005T3 (da) | Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd | |
BR9712307A (pt) | Pirazolinonas para o tratamento de potência enfraquecida | |
PT1152757E (pt) | Inibidores de mmp no amolecimento do tecido conjuntivo | |
BR9813539A (pt) | Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20110104 |